Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement
Status:
Active, not recruiting
Trial end date:
2021-09-17
Target enrollment:
Participant gender:
Summary
Preliminary data support the effect of Nitric Oxide (NO) on improving the oxygenation in
mechanically ventilated patients and spontaneously breathing patients with COVID-19. In vitro
studies showed an antiviral effect of NO against SARS-coronavirus. The optimal therapeutic
regimen of NO gas in spontaneously breathing hypoxemic patients with COVID-19 is not known.
We hypothesize that high concentration inhaled NO with an adjunct of continuous low dose
administration between the high concentration treatments can be safely administered in
hypoxemic COVID-19 patients compared to the high dose treatment alone. Prolonged
administration of NO gas may benefit the patients in terms of the severity of the clinical
course and time to recovery. Together with a clinical effect on ventilation-perfusion
matching, a prolonged regimen would allow also an increase in antiviral activity (dose and
time-dependent).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Federal State Budgetary Scientific Institution, Research Institute of Cardiology Tomsk National Research Medical Center of the Russian Academy of Sciences